Incyte strikes pair of Jakafi deals in GvHD

Eli Lilly & Co. (NYSE:LLY) granted Incyte Corp. (NASDAQ:INCY) rights to myelofibrosis drug Jakafi ruxolitinib

Read the full 152 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE